The second one stated, in 2019, that ACT and personalized vaccines can successfully treat recurrent GISTs [258]; eight refractory recurrent GIST patients were intravenously administrated with allogenous phytohemagglutinin (PHA)-activated T cells, personalized vaccines and low dose of interleukin-2, and 5 of them showed remissions, 1 had SD and 2 had PD after a 14-month follow-up study [258], suggesting that this therapy was safe and effective, at least for some GIST patients [258]. Here, IL2 is linked to gastrointestinal stromal tumor.